Ocugen (OCGN) Projected to Post Earnings on Thursday

Ocugen (NASDAQ:OCGN) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $0.9760 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, July 31, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last posted its earnings results on Tuesday, May 5th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.42 million. On average, analysts expect Ocugen to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ocugen Price Performance

Shares of NASDAQ:OCGN opened at $1.29 on Thursday. The firm’s 50 day moving average is $1.37 and its two-hundred day moving average is $1.59. Ocugen has a 52 week low of $0.93 and a 52 week high of $2.73. The firm has a market capitalization of $436.69 million, a P/E ratio of -5.38 and a beta of 2.18. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 4.17.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on OCGN shares. HC Wainwright boosted their price objective on Ocugen from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Weiss Ratings cut Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Ocugen in a research note on Wednesday, March 25th. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Canaccord Genuity Group decreased their price target on Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Activity at Ocugen

In related news, CFO Treerita Essali Johnson-Greene purchased 21,000 shares of Ocugen stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $1.23 per share, with a total value of $25,830.00. Following the purchase, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. The trade was a 4.20% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.95% of the company’s stock.

Institutional Investors Weigh In On Ocugen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OCGN. SmartHarvest Portfolios LLC bought a new stake in Ocugen during the fourth quarter worth approximately $31,000. NewEdge Advisors LLC boosted its stake in Ocugen by 198.0% during the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after purchasing an additional 24,460 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after purchasing an additional 13,326 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Ocugen during the 4th quarter valued at $38,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Ocugen by 28,222.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after buying an additional 30,198 shares in the last quarter. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.